Development sources

Evidence sources

The documents below contain clinical guideline recommendations or other recommendations that were used by the TEG to develop the quality standard statements and measures.

Ovarian cancer: the recognition and initial management of ovarian cancer. NICE clinical guideline 122 (2011; NHS Evidence accredited).

Trabectedin for the treatment of relapsed ovarian cancer. NICE technology appraisal guidance 222 (2011; NHS Evidence accredited)[1].

Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. NICE technology appraisal guidance 91 (2005)[1].

Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE technology appraisal guidance 55 (2003)[1].

The Royal College of Radiologists (2012; NHS Evidence accredited). iRefer: Making the best use of clinical radiology: referral guidelines.

Policy context

It is important that the quality standard is considered alongside current policy documents, including:

Department of Health (2011) Improving outcomes: a strategy for cancer.

Department of Health (1999) Improving outcomes in gynaecological cancers: the manual.

Definitions and data sources

References included in the definitions and data sources sections can be found below:

Department of Health (2011) The operating framework for the NHS in England 2011/12.

National Cancer Intelligence Network (expected publication July 2012) National Cancer Outcomes and Services Dataset.

National Cancer Peer Review Programme (2008, updated 2011) Manual for cancer services: gynaecological measures.

NICE ovarian cancer audit support (NICE clinical guideline 122) (2011).



[1] NICE technology appraisal guidance 55, 91 and 222 were used in development only and were not used as evidence for the final standard.